In partnership with
Good Morning! This exclusive edition of The Funding Letter comes to you from our headquarters in New York City. 🔥New Sales Gigs from Agentio below!
Hit the Gong 🎉
Source: @overheard_sales
Investor-ready Startup Financials
Last year, we helped companies raise $300M in venture capital. Next week, we are running a 1-week LIVE workshop that covers:
Financial modeling basics
How to forecast startup growth
Budgeting rounds of funding
Daily Deals 💸
🌎 Americas
🧬 Lycia Therapeutics has developed a novel therapeutic that degrades extracellular and membrane-bound proteins driving a range of difficult-to-treat diseases, such as cancers and autoimmune conditions. View on: LinkedIn.com | Sales Navigator.
New Funding Raised: $106.6M, Series C
Round Investors: Venrock Healthcare Capital Partners (lead), Redmile Group, Alexandria Venture Investments, Invus
🚀Growth Focus: Advance its lead programs into the clinic for autoimmune and inflammatory diseases.
Press: GlobeNewswire, BioSpace
HQ: San Francisco, CA
Industry: Biotechnology Research
Employee Count: 41
🧬 Ajax Therapeutics is a biotechnology company focused on developing targeted therapies for hematologic cancers, allowing patients with hematologic malignancies to address significant unmet needs. View on: LinkedIn.com | Sales Navigator.
New Funding Raised: $95M, Series C
Round Investors: Goldman Sachs Asset Management (lead), EcoR1 Capital, Vivo Capital, RA Capital Management
🚀Growth Focus: Support the clinical development of its first-in-class Type II JAK2 inhibitor, AJ1‑11095, for the treatment of myelofibrosis, advancing its pipeline of treatments for MPNs.
Press: Business Wire, Global Genes
HQ: Cambridge, MA
Industry: Biotechnology Research
Employee Count: 6